Monitoring molecular changes in the brain caused by cancer and other neurological pathologies in a non-invasive way is one of ...

Thymalfasin is under clinical development by SciClone Pharmaceuticals and currently in Phase II for Thymoma (Thymic Epithelial Tumor). According to GlobalData, Phase II drugs for Thymoma (Thymic ...

The characteristics of hydrolysis of triglycine by thymus homogenates from normal mice were investigated ... This work was supported by a grant from the National Cancer Institute of Canada to Dr.

Thymectomy in rodents shortly after birth led to the development of autoimmune responses (3), highlighting the regulatory role of the thymus. By the mid-1970s ... by activated T cells was considered a ...

A spinal cord tumor is an abnormal tissue growth within or next to the spinal cord. Even benign spinal cord tumors can cause serious neurological problems in your child because they can put pressure ...

Expert Rev Mol Diagn. 2008;8(5):579-585. Quite a few tumor markers (CEA, CA 19-9, AFP, SCC, CA 72-4.) have already been established in diagnosis and/or surveillance of malignant diseases of the GI ...

(RTTNews) - Immuno-oncology company Marker Therapeutics, Inc. (MRKR) announced Tuesday that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of ...

The publisher has been closely monitoring the various markets in Saudi Arabia. This report provides a comprehensive analysis, detailing market size, forecast, trends, growth drivers, and challenges.

Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education Chongqing, College of Chemistry and Chemical Engineering, Southwest University, Chongqing ...